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1. Introduction
This chapter introduces biochemical pharmacology and highlights drug absorption and drug
transformation reactions and a general introduction to pharmacology, drug discovery and
clinical trials for new drug candidates. It also introduces the concept of individualization of
drug therapies. After studying this chapter, one is expected to demonstrate understanding the
following: (i) Linkage between the various pharmacological processes (ii) Routes of drug
administration, (iii) Mechanisms of drug absorption (iv) The kinetics of drug disposition and
concepts, such as volume of distribution, initial dose and half-life, (v) The biotransformation
and excretion of drugs.(vi) The role of biochemical knowledge in the discovery and develop‐
ment of candidate drug compounds into useful drugs (vii) Basic design of clinical trials of new
drugs and the drug approval process.(viii) The linkage between genetic variations and varied
drug responses in different individuals (ix) The various adverse drug reactions in different
patients (x) How different dosage regimens are calculated with respect to the prevailing health
status of individuals and how adjustments are carried out in old patients or geriatrics.
2. Pharmacology
Pharmacology is the science that deals with drugs, their properties, actions and fate in the
body. It embraces the sciences of pharmaceutics (preparation of drugs), therapeutics (treat‐
ment of diseases by use of drugs) and toxicosis or adverse side-effects that arise from the
therapeutic interventions. Pharmacology can be divided into the following processes:-
i. The pharmaceutical process of drugs; deals with chemical synthesis, formulation and
distribution of drugs.
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ii. Pharmacokinetic process; deals with the time course of drug concentration in the
body.This process can be further subdivided into; absorption, distribution, biotrans‐
formation and excretion of the drug.
iii. The pharmacodynamic process; deals with the mechanism of drug action: that is
interaction of drugs with the molecular structures in the body.
iv. The therapeutic process; deals with the clinical response arising from the pharmaco‐
dynamic process.
v. Toxicologic process; deals with adverse effects of drugs arising from either over
dosage or interference of biochemical pathways unrelated to the intended drug
target. The five processes are related as exemplified in Figure1.
3. Biochemical pharmacology
Biochemical pharmacology is concerned with the effects of drugs on biochemical pathways
underlying the pharmacokinetic and pharmacodynamic processes and the subsequent
therapeutic and the toxicological processes. The pharmaceutical process is, however, outside
the realms of biochemical pharmacology.
4. Routes of drug administration and systemic availability
This depends on the actual biochemical characteristics of the drug and the interaction of drug
molecules with body fluids and tissues. The main routes of drug administration are the topical
application, parenteral, and enteral routes.
The route of drug application determines how quickly the drug reaches its site of action. The
choice of the route of administration of a drug, therefore, depends on the therapeutic objectives
of the treatment. For instance, intravenous injection or inhalation may be selected to produce
intense, but rather short-lived effects, whereas oral dosing may be better and more convenient
for long lasting effects and even intensity. The various types of drug administration include;
4.1. Topical application
This is the most direct and easiest mode of drug administration. It involves local application
of a drug to the site of action e.g. eye drop solutions, sprays and lotions for oral, rectal, vaginal
and urethral use. These drugs are absorbed through the cell membranes. Absorption of drugs
through the skin is proportional to their lipid solubility since the epidermis behaves like a
hydrophilic barrier. Lipid insoluble drugs are therefore suspended in oily vehicles to enhance
solubility and hence absorption.
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Figure 1. Relationships between the five pharmacological processes starting with the entry of the drug and ending
with the clinical response and/or the toxic effects
4.2. Oral administration
The drugs administered orally are absorbed at different sites along the gastrointestinal tract
(GIT):
4.2.1. Oral mucosal or sublingual
Drug absorption is generally rapid because of the rich vascular supply to the mucosa and the ab‐
sence of a stratum corneum. Drugs delivered using this route are not exposed to gastric and in‐
testinal digestive juices and are not subjected to immediate passage through the liver. Therefore
there is no prior biotransformation or first-effect before the drugs enter the systemic circulation.
4.2.2. Stomach and intestine
Absorption depends on different factors such as pH, gastric emptying, intestinal motility and
solubility of solid drugs. The rapidity with which a drug reaches the small intestine is enhanced
when a drug is taken with water and when the stomach is relatively empty. However drugs
absorbed in the stomach and intestine are subjected to first-pass effect.
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4.3. Rectal administration
This is the preferred route when the oral route is unsuitable because of nausea or if the
drugs  have  objectionable  taste  or  odor.  This  route  also  protects  susceptible  drugs  from
the biotransformation reactions in the liver. However, absorption by this route is often ir‐
regular  and  incomplete.  Formulations  such  as  suppositories  or  enemas  are  applied  via
rectal route.
4.4. Parenteral administration
This mode of administration is also known as injection. It is generally more rapid and enables
more accurate dose selection and predictable absorption. Parenteral routes include;
4.4.1. Subcutaneous injection
This mode of administration is mainly used for non-irritating drugs. It provides even and slows
absorption producing sustained drug effects. Vasoconstrictor agents such as epinephrine can
be added to the drug solution to decrease the rate of absorption.
Large volumes of drugs may, however, be painful because of tissue distention.
4.4.2. Intramuscular injection
This method of drug delivery ensures rapid absorption of the drug in aqueous solutions. Slow
and even absorption is possible when drugs are suspended in oily vehicles.
4.4.3. Intravenous administration
This route ensures rapid delivery of the desired blood concentration of the drug to be obtained
accurately and immediately and is the preferred route of delivery in emergency situations.
Irritating drugs are delivered intravenously because the veins have low sensitivity to pain.
This mode of delivery is also preferred for drug such as the barbiturates and phenytoin, anti-
seizure drugs which dissolve only in rather strong alkaline solution and therefore need the
blood to buffer the pH of the drug solution for better solubility. Drugs such as ethylene di-
amine tetra acetic acid (EDTA) for treatment of heavy-metal poisoning are given by intrave‐
nous injection or through an infusion because they are poorly absorbed in the gut. The other
advantage of this mode of delivery is the avoidance of the hepatic and pulmonary first-pass
effect. Generally, the properties of the drug may determine the route that must be used for
reasonable efficacy.
5. Mechanisms of drug absorption across membranes
In order for drugs to elicit their pharmacological effects, they have to cross the biological
membranes into systemic circulation and reach the site of action. Therefore an insight into the
structure and function of the membrane leads to a better understanding of drug absorption.
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Membranes are phospholipid bi-layers with interspersed integral and peripheral proteins
which behave either as molecular ‘gates’ or ‘pumps’. Molecular gates are non-specific. The
intake of molecules into the cell depends on the charged groups in the pore and the size of
molecule to be transported across the membrane. Molecular pumps, however, are highly
specific and require energy for molecular transport. There are several mechanisms by which
drugs traverse membranes to reach their intended target site and they include the following:
5.1. Simple diffusion
This involves is the passage of polar but uncharged substances across water filled chan‐
nels  in  response  to  the  concentration  gradient.  Simple  diffusion  is  the  mechanism  of
choice for water soluble drugs and those with low molecular weight such as the an aes‐
thetic  nitrous  oxide  (44kD)  and  ethanol  (46  KDa).  The  majority  of  lipid-soluble  drugs
permeate cell  membranes by passive diffusion between the lipid molecules of the mem‐
brane.  The permeation rate of  a  lipid soluble drug depends on the concentration of  the
drug, its lipid/water partition coefficient concentration of protons and the surface area of
the absorbing membrane.  The lipid/water  partition coefficient  of  a  drug is  the principal
factor determining its absorption.
The  higher  the  value  of  lipid/water  partition  coefficient  of  a  drug,  the  more  rapidly  it
will  be  absorbed  and  vice  versa.  The  chemical  force  that  causes  lipid-soluble  drugs  to
move readily across  membranes is  termed the hydrophobic  force since water  molecules
repels  the  lipid-soluble  drugs.  In  most  cases,  drug  absorption  can  be  enhanced  by  ab‐
sorption  enhancers,  such  as  fatty  acids,  phospholipids  and  muco-adhesive  polymers.
These compounds disrupt the lipid bilayer making it  more permeable and also increase
the solubility of insoluble drugs.
5.2. Facilitated diffusion
This type of diffusion is achieved by carrier molecules which combine with the drug in question
to form complexes that can diffuse more rapidly across the membrane than free-drug could
do alone. An example is the transport of nucleotide antimetabolites used in viral or cancer
chemotherapy.
5.3. Active transport of drugs
This is the transport which is linked to a source of energy. Examples of specific active transport
systems are the sodium pump, which maintains high potassium and low sodium ions inside
the cell relative to the external medium and the calcium pump that maintains a high concen‐
tration of calcium inside the sarcoplasmic reticulum and a low concentration around the
myofibrils. Active transport of drugs across membranes have been discovered and an example
is the uptake of pentazocine (a narcotic antagonist) by leukocytes which is dependent upon
energy supply (glucose) and can be inhibited by cyclazocine, which competes for the same
transport mechanism.
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5.4. Pinocytosis and phagocytosis of drugs
Proteins, bacterial toxins and drugs with high molecular weights, (1000 KDa or more) en‐
ter cells by means of pinocytosis and endocytosis. These substances finally enter the lyso‐
somal system.
6. Factors affecting absorption of drugs
6.1. Surface area
For any substance that can penetrate the GIT in measurable amounts, the small intestine
represents the greatest area of absorption. For instance, ethanol can be absorbed by the
stomach, but it is absorbed eight times faster from the small intestine because of the large
surface area provided by the villi. The rate at which the stomach empties its contents into the
small intestine also markedly affects the overall rate at which drugs reach general circulation
after oral administration. For this reason many agents are administered on an empty stomach
with sufficient water to ensure their rapid passage to the small intestine.
6.2. Tissue pH
Drugs can be classified either as organic amines or organic acids and therefore their absorption
is markedly affected by pH. Tertiary amines are not charged at high pH and have a high lipid/
water partition coefficient and hence readily penetrate membranes.
At low pH, the tertiary amine is protonated and has low lipid/water partition coefficient thus
lower rate of permeation.
N
RR
R H
+ N
R
R
R
Small intestines
High pH
(unprotonated form)
Higher absorption.
+ H+
Stomach
Low pH
(protonated form)
Lower absorption
In case of an organic acid, the same general principle applies. The unprotonated organic acid
at low pH permeates the tissues more readily as compared to the charged form of the drug
at high pH.
Low pH High pH
R-COOH ⇌ R – COO-+ H+
Stomach Intestine
Drug Discovery480
Therefore organic acids such as barbiturates and acetyl salicylic acid (aspirin) have a higher
absorption rate in the stomach.
The degree of ionization of the drug when in the GIT or other body fluids is the main deter‐
minant of the amount of the drug found in an uncharged form and this depends upon the
relation between pH of the fluid and the pKa of the drug:
Acidic drugs:
RCOOH⇌
Ka
RCOO-+ H+
Basic drugs:
R –+NH3⇌
Ka
RNH2+ H+
If the pH of the fluid is low, the ionization of acidic drugs is less while the ionization of basic
drugs will be high.When the pKa of a drug is equal to the pH of the surrounding fluid, there
is 50% ionization.
7. Types of tissue barriers to drugs
Most of these barriers are typically the same systems that animals use for defense against
invasion by foreign agents. These barriers include the skin, the GIT membranes, blood-brain
barrier and placenta.
7.1. Skin
The superficial layer of the skin, stratum corneum is particularly impermeable to most drugs.
The skin permeability for the drugs is enhanced by using a co-solvent system such as ethanol/
water which increases drug partition into the skin. The lipid domains of the buccal and nasal
mucosa also restrict drug entry and the drugs which permeate are able to do so through passive
diffusion using the hydrophilic trans-cellular spaces and direct permeation through the
membrane.
7.2. Tight junctions
The gap junctions between cells in different cell types within a tissue can form channels for
the passage of drugs between epithelial, endothelial, and mesothelial cells of the same tissue.
These channels comprise of a group of proteins known as connexin. Cells in different tissues
are however connected by tight junctions and these can impair transport between cells in
different tissues. The tight junctions are dynamic structures, which normally regulate the
trafficking of nutrients, medium sized compounds between cells, and form a regulated barrier
in spaces between cells. There is need therefore to use drug absorption enhancers such as bile
salts and long chain acyl-carnitines which act as Ca2+chelatorsand disrupt the tight junctions
thereby improving transport across the junctions. Tight junctions are shown in Figure 2.
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Figure 2. Arrangement of epithelial cells with tight junctions
7.3. Cerebrospinal fluid barrier (CSF)
Epithelial cells which are in contact with the brain ventricular spaces form a barrier to the
movement of drugs. These epithelial cells are connected by occluding zonulae (blood- brain
barrier) as shown in Figure 3. The zonulae severely restrict the passage of most molecules
between the bloodstream and the parenchyma of the central nervous system. Drug entry across
this barrier is through either passive diffusion or carrier mediated transport. Only the lipid
soluble drugs cross into the CSF from blood.
Figure 3. Epithelial cells with tight junctions as part of the blood brain barrier
Epithelial cells that separate the CSF from the brain are connected with tight junctions and are
characterized by marked scarcity of pinocytic vesicles. However, the epithelial cells that lines
the brain are not connected by occluding zonulae and therefore, there is unrestricted passage
of drug molecules from CSF to the brain. Drugs like penicillin which are not much lipid-soluble
and required in high concentrations for the treatment of brain abscesses are administered
through intrathecal injections directly into the CFS.
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7.4. Placental barrier
The placental membrane limits the amount of maternal blood following through the placenta
to the foetus and passive diffusion is the main mechanism of drug entry from the maternal
blood to the foetus. The shortest time required for equilibration of a drug between mother and
foetus is about ten minutes and this delay is useful as it can allow a mother to be anaesthetized
during final stages of labour.
8. Systemic availability of drugs
A drug will reach systemic arterial circulation only if it is absorbed from the GIT and if it
escapes metabolism in the gut, liver, and lungs. When the concentration of the drug in plasma
is measured at specified time intervals, it is possible to construct concentration versus time
graph and hence be able to determine the extent of drug availability as shown in Figure 4.
The availability depends on both the extent of absorption and the extent of presystemic metabo‐
lism and comprises three aspects; Peak concentration (Cmax), Time taken to reach the peak (Tmax)
and area under the curve (AUC)as shown in Figure 4. The Cmax and Tmax are measures of the rate
of availability while AUC is a measure of the extent of availability (i.e. proportion of the admin‐
istered drug which reaches systemic circulation intact). For the three curves shown for the for‐
mulations a, b, and c; the AUC is the same, but the rate of availability is different in each case; a,
has the lowest rate of availability followed by b, while c has the highest rate of availability.
o
o
o
o o o
abc
Increased risk of toxicity
Minimum effective concentration[Pl
asm
a]
Time (minutes)
Tmaxc Tmaxb Tmaxa
Cmaxa
Cmaxb
Cmaxc
Figure 4. Plasma concentration versus time curves for different drug formulations
The speed at which a particular drug is needed to reach the site of action will determine the type
of formulation to use. Drugs with the same relative bioavailability and can be used to treat the
same condition using either the same routes or dosages are known as bioequivalent drugs.
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9. Dosage and effect
A particular dose of an administered drug is subject to the biochemical processes in the body
as shown in Figure 5. The desired effect of a drug is proportional to the concentration of the
drug at its site of action which is described by the following kinetic parameters: (i) The apparent
volume of distribution (Vd) which is the volume of the hydrophilic and hydrophobic spaces
in the body that the drug is distributed in. It is obtained by dividing the injected dose (Do) by
the initial concentration (Co) in blood plasma. Drugs that bind to tissues extensively exhibit
low concentrations in the plasma and therefore, have higher a Vd compared to those that are
mainly bound by blood plasma proteins. An average 70kg person has a total body water
volume of ~ 50L of which ~ 10L occupy extra-cellular space.
Locus of action
ReceptorBound 
drug Freedrug
Tissue deposits
Bound
drug Freedrug
    Plasma
Free drug
Metabolites
Biotransformation
ExcretionAbsorption
Figure 5. Drug disposition routes from absorption to excretion
The apparent volume of distribution cannot tell us where in the body the drug really is. The
(Ctox) is the maximum drug concentration beyond which there would be toxic effects in the
body, while the (Cther) is the plasma concentration of a drug that would achieve a therapeutic
effect or effective clinical response. The steady state concentration (Css) is that concentration
that should be maintained between any two drug administration intervals. These pharmaco‐
kinetic data are important in that they characterize the fate of drugs in the body and are
required by pharmacologists to calculate doses and frequencies of drug administration.
However, in some clinical responses, the intensity of pharmacological action correlates better
with the concentration of free drug in plasma, while in other responses there is no direct
relationship between drug concentration and clinical response. The main variations of the drug
response effects include;
i. Drugs which combine with their receptors as quickly as they dissociate from them;
for this category of drugs, the pharmacological effect increases or reduces in tandem
with the plasma drug concentration.
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ii. Drugs which do not readily dissociate from their receptors. In this case the pharma‐
cological effect persists despite the falling plasma concentration.
iii. Drugs which combine with receptors and irrespective of their rates of association/
dissociation sets in motion a cascade of events which runs on despite falling plasma
concentrations.
10. Kinetics of drug disposition process
Drug disposition process most of the times follows the 1st order kinetics in which disposition
is proportional to the concentration of the drug at any given time. Therefore, the concentration
of a drug in plasma will decrease at a rate that is proportional at all times to the concentration
itself. Therefore;
-d C
dt  =  K C
∫ -d CC =  ∫Kdt 
=In[C] ct
co
Kt
In[C]t In[C]o- = Kt or InC InCo= - Kt
eIn [C]t
[C]o e
-Kt
[Ct] [Co]
=
= e-Kt
A more convenient form of this equation is obtained by taking log10
Since
ln x =  2.303log10 x (1)
It follows that;
2.303log10 C =  2.30.3log10 C0 - Kt
and log10 C=log10 C0 -  Kt2.303
A linear relationship is obtained when the logarithm of concentrations (log10C) is plotted
against (t), times of observation (Figure 6).
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y-intercept = log10 Co
slope = -K
2.303
log10C
Time (Hrs)
Figure 6. Logarithmic time course of drug concentration
Half-life (t1/2) of a drug: this is the time period during which the concentration decreases to
one- half of its previous value. T 1/2 can be evaluated from the elimination rate constant.
When t = t1/2, Ct = 
C0
2
therefore,
C0
2 =C0e -K t1/2
1
2 = e -K t1/2   but,     Kt1/2 =  loge 2
t1/2 = loge 2K =  0.693K
11. Drug biotransformation reactions
Drugs and other foreign substances (xenobiotics) undergo series of biotransformation reac‐
tions in the body. The biotransformation reactions act as first line defense strategy against these
xenobiotics. It is armed with a battery of enzymes which convert the lipid-soluble xenobiotics
into more water-soluble metabolites to allow more efficient excretion of the drugs in a limited
volume of water in urine or bile.
The enzymes involved in the biotransformation of endogenous chemicals are the same ones
that are used in the biotransformation of xenobiotics. There is, therefore, a close relationship
between drug biotransformation and fundamental homeostatic processes.
The drug biotransformation reaction may result in the following potential effects with respect
to pharmacological activity:
11.1. Activation
An inactive precursor may be converted into a pharmacologically active drug. For instance,
the nucleoside analogue used as an anti-HIV drug, have to undergo in vivo phosphorylation
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to form the active triphosphates which functions to inhibit the enzyme reverse transcriptase,
while L– dopa (inactive), which is used in the treatment of parkinsons disease, is converted
into dopamine (active) in the basal ganglia. Futamide, a drug used in the treatment of prostate
cancer, undergoes hydroxylation at the alkyl side chain to form hydroxyflutamide, a metab‐
olite that is more active and has a longer duration of action compared to the parent drug.
11.2. Maintenance of activity
An active drug is converted into another form which is also active, for instance diazepam, a
sedative hypnotic, is metabolized to an equally active metabolite, oxazepam.
11.3. Inactivation
An active drug is converted to inactive products, for example, pentobarbital is hydroxylated
to forminactive metabolites.
11.4. Phase I reactions
These include oxidation, reduction and hydrolytic reactions and such reactions generally
introduce or unmask a functional group (hydroxyl, amine, sulfhydryl etc) that make the drug
more polar.
11.5. Phase II reactions
Consist of synthetic/conjugation reactions in which an endogenous substance such as glucur‐
onic acid or glutathione combines with the functional group derived from phase I reactions to
produce a highly polar drug conjugate. All tissues have some ability to carry out drug
biotransformation reactions but the most important organs of biotransformation include; the
liver, GIT, lungs, skin, and kidneys in that order and most phase II reactions result in a decrease
in the pharmacological activity of the drug. The fact that the GIT and liver are the major sites
of drug biotransformation means that drugs which are administered orally will be extensively
bio-transformed before they eventually reach systemic circulation. This first-pass effect can
severely limit the oral bio- availability of some drugs. In addition, intestinal micro-organisms
are capable of catalyzing drug biotransformation reactions e.g. a glucuronide conjugate of a
drug may be excreted through the intestine via the bile where gut bacteria may convert the
conjugate back into free drug. The free drug is then reabsorbed and re-enters the liver via the
portal vein where the conjugation process is repeated. This leads to a phenomenon known as
entero-hepaticcirculation.
At sub-cellular level, enzymes of drug biotransformation are located in the endoplasmic
reticulum, mitochondria, cytosol and lysosome. The major site of drug biotransformation
within the hepatocytes and other cells is the membrane of the smooth endoplasmic reticulum.
The smooth endoplasmic reticulum constitutes the microsome fraction during differential
centrifugation of whole blood. The microsome fraction can be used to carry out many drug
biotransformation reactions in vitro.
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11.6. Mechanisms of phase I reactions
11.6.1. Oxidation
Is the most important category of the microsomal drug oxidizing systems and requires partici‐
pation of two distinct proteins in endoplasmic reticulum; cytochromes P450 (which functions as a
terminal oxidase) and cytochrome P450 reductase. The name Cyt450 is derived from the fact that
the reduced form of this hemoprotein complexes with carbon monoxide to form a complex that
has a unique absorption spectrum with a maximum at 450nm.Cytochrome P450 reductase serves
to transfer reducing equivalent from NADPH to the cytochrome P450 oxidase:
DrugRH + O2+ NADPH + H+ → DrugROH (hydroxylated product) + H2O+ NADP+
The sequence of reactions that transform a drug to its hydroxylated product is shown below
(Figure 7).
NADPH
(RH) Fe3+ROH
(RH)Fe2+
(ROH) Fe3+ O2
(RH) Fe2+.O2
RH.Fe3+.O22-
H2O
2H+
Fe3+
cytP450
(R.)(Fe - OH)3+
(Binary complex)
RH (The drug binds to cyt. P450
oxidase)
NADPH - cyt.
P450 reductase
e-
(Ternary complex)Abstraction of
H from substrate
results in the
formation of substrate 
radical and hydroxyl
The O - O bond is split 
with the uptake of 2 protons. 
 The result is the release of 
 H2Oand generation of  an "activated oxygen"
Cofactor 
donates
a proton
(RH).Fe3+.O2 -
(RH)(Fe-O)3+
(R)(Fe - OH)3+
cyt b5 2nd e- transfer
is required
to activate
the bound O2-NADH - NADH
cyt b5 reductase
The dissociation of 
ROH and restoration of 
the ferric form of cyt P450
Figure 7. Phase 1 drug biotransformation reactions in the liver microsomal fraction in which the drug is converted to a
more polar form.
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The phospholipids of the endoplasmic reticulum are required for substrate binding, electron
transfer, and facilitating the interaction between CytP450 and its reductase. However, cyto‐
chrome P450 does not catalyze all Oxidation reactions. The microsomal flavin– containing
monooxygenases (FMOs) catalyze NADPH – dependent oxygenation of nucleophilic phos‐
phorous, nitrogen and sulfur atoms. These atoms are present in a wide variety of xenobiotics
including the carbamate containing pesticides and therapeutic agents such as phenothiazines,
ephedrine and N-methylamphetamine. Another important drug–oxidizing system is the
prostaglandin synthetase–dependent co-oxidation.
Prostaglandin G2 reduced
prostaglandin
 synthetase
prostaglandin H2
Many xenobiotics  including  phenytoin  can  be  co-oxidized  along  with  the  above  reduc‐
tion reaction.  This  pathway is  of  considerable  toxicological  importance  as  it  often leads
to  generation  of  toxic  reactive  metabolites.  Other  enzymes  that  catalyze  oxidation  of
xenobiotic  include  alcohol  dehydrogenase,  aldehyde  dehydrogenase,  xanthine  oxidase
and monoamine oxidase.
11.6.2. Reduction
Some drugs with azo-linkages (RN=NR, e.g. prontosil) and nitrogen groups (RNO2, such as
chloramphenicol) are transformed by reductive pathways. The Cyt P450 and NADPH–cyt
P450reductase enzymes that catalyze oxidation reactions are also involved in reduction
reactions for drugs containing quinine moieties. These transformation results in the formation
of semiquinone free radicals illustrated in Figure 8. The free radicals that are generated cause
oxidative stress, lipid peroxidation, DNA damage, and hence cytotoxicity. These effects are
particularly responsible for the antitumor property of a drug like doxorubicin.
11.6.3. Hydrolysis
Drugs containing ester functions (R1COOR2) such as procaine are hydrolyzed by a variety of
non-specific esterases in liver, and plasma while drugs with amide bonds are hydrolyzed by
amidases in the liver. The polypeptide drugs such as insulin and growth hormones are
hydrolyzed by peptidases in the plasma and erythrocytes. The metabolites resulting from
hydrolysis reactions are subjected to phase II biotransformation reactions before excretion in
the bile or urine.
11.7. Mechanisms of phase II reactions
The phase II reactions generally involve coupling of drug/drug metabolite with an endogenous
substance to enhance their removal from the body. They require participation of specific
transferase enzymes and high energy activated endogenous substances.
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Most of the conjugation reactions result in detoxification of the drug although in some cases
conjugation reactions result in bioactivation of drugs. The following is a summary of the
different types of phase II biotransformation reactions;
NADP+NADPHO OH
O
NAD(P)H O.
O O2O2-
H2O2
OH . OH
2 e-
Hydroquinone
1e
NADPH -
cytochrome P450
reductase
detoxification
semiquinine
NAD(P)+
Quinone
Figure 8. The transformation pathways for drugs with quinine moieties to generate free radicals.
11.7.1. Glutathione conjugation
Glutathione-S-transferases catalyze the enzymatic conjugation of xenobiotics with the endog‐
enous tripeptide glutathione, glutamylcystenylglycine (GSH). The xenobiotics with suitable
electrophilic centres such as the epoxides and nitro groups can be subjected to nucleophilic
attack by glutathione (Figure 9). The final product, mercapturic acid is easily excreted from
the body.
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Glu - Cys - Gly + drug X
Glutathione - S 
- transferase
Glu - Cys - Gly
SX
Glutamyl transpeptidase
Glutamylamino
acidCys - Gly
Cysteinylglycinase
Gly
Cys
Acetyl CoA
Acetyltransferase
N- Acetyl - Cys - SX
(Mercapturic acid)
SX
CoA
H2O
SH SX
Amino acid
Figure 9. Glutathione conjugation reactions for a drug with a suitable nucleophilic centre leads to the formation of
mercapturic acid which is easily excreted from the body
11.7.2. Glucuronidation
This is the conjugation of a drug or xenobiotic with glucuronic acid. Many functional groups
are subject to glucuronidation. The benzoyl group in morphine, (an analgesic) and the amine
group in meprobamate (a sedative) can undergo glucuronidation. A drug with a benzoyl group
can undergo glucoronidation by a transferase as shown below:
OH
HOOC
OHUDPGA transferase+
Benzoyl
glucuronide
+ UDP
Benzoyl group
O
H
OH H
Glucuronyl
C
C
O
O O
R
R
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11.7.3. Epoxide hydration
A number of aromatic compounds are transformed by phase I reactions to form epoxide
intermediates. The epoxides are reactive electrophilic species that can bind covalently to
proteins and nucleic acids to bring about toxic effects. These epoxides are detoxified via the
nucleophilic attack of water molecule on one of the electron deficient carbon atoms of the
oxizane ring as shown below:
R2R1
CHCH
Drug substrate - epoxide
+ H H+epoxide
hydrolase
R1
CH
R2
OH
CH
OH
OH
O
The glucuronide conjugates can be excreted via the bile or urine.
11.7.4. Acetylation
Acetylation  is  achieved  by  cytosolic  enzymes  known  as  N-acetyl  transferases  which
catalyze  transfer  of  acetate  from acetyl  co-enzyme A to  primary aromatic  amine or  hy‐
drazides (figure 10)
Acetate + CoA CH3
C
CoA
Acetyl CoA
SO2 NH2
Sulfanilamide
N- a
cety
l
tran
sfer
ase
CH3
H
N
N- acetylsulfanilamide
O
C
O
S
H2N SO2 NH2
SH
Figure 10. Acetylation reations leading to the formation of N– Acetylsulfanilamide, the final metabolite of the antimi‐
crobial agent sulfanilamide which is secreted from the body.
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11.7.5. Methylation
Most of the methyl transferases are cytosolic enzymes. They utilize S-adenosyl methionine
(SAM) as the methyl donor. The final metabolite, thiopurine, has antineoplastic properties and
is used as an anticancer agent (Figure 11)
Figure 11. Methylation reactions leading to the formation of methylthiopurine
12. Adverse drug reactions associated with drug biotransformation
reactions
Many adverse  drug  reactions  can  be  traced  to  an  improper  balance  between  bioactiva‐
tion and detoxification reactions. For example, when the analgesic acetaminophen is giv‐
en at normal therapeutic doses, it undergoes glucuronidation and sulfation reactions that
terminate the action of the drug and hasten its elimination. However,  some of the drug
is bioactivated via Cyt P450  to form N-acetylbenzoquinimine, a reactive intermediate that
can  be  detoxified  by  conjugation  with  glutathione  (GSH).  When  excessive  doses  of  the
drug are given, glucuronidation and sulfation reactions become saturated and more acet‐
aminophen is bioactivated via Cyt P450. This imbalance leads to high concentrations of N-
acetylbenzoqunonine  which  cannot  be  sufficiently  eliminated  by  the  limited
concentrations of gluthathione. This metabolite binds covalently to cellular protein thiols
and initiates hepatotoxicity leading to hepatic necrosis.
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12.1. Revision exercise 1
1. Discuss the absorption of ά-D- Ribose-5-phosphate, given that the two ionizable hydroxyl
groups of the monophosphate ester ribose have pKa values of 1.2. and 6.6. The fully
protonated form of ά-D-ribose 5-phosphate has the following structure;
H
P O
O
H
CH2
OH
HO O
OH OH
OH
H
2. Using specific examples of drugs, justify their various routes of administration.
12.2. Revision exercise 2
If the concentration of a drug in plasma decreases at a rate that is proportional to its initial
concentration, give an expression that describes this relationship and hence show that [Ct] =
[Co].e-kt
12.3. Worked examples
Problem 1: Describe how you can determine the partition coefficient of a labeled drug
Solution: The partition coefficient of a drug is its differential distribution between the
hydrophobic and hydrophilic phases. The distribution of the drug between these two phases
can be determined by allowing equilibration of a radioactively labeled drug between aqueous
buffer containing the drug and a cell membrane preparation obtained by homogenization and
fractionation of a tissue sample. The ratio of drug concentration in the membrane to the
concentration in the aqueous phase gives the partition coefficient.
Problem 2: Describe how you can demonstrate transport across membranes
Solution: Erythrocyte ‘ghosts’ or self sealing micelles formed when the erythrocytes release
cytoplasmic contents upon exposure into a hypotonic solution can be used to study the uptake
or release of labeled molecules across erythrocytes. When the ghosts are prepared in 14C
glucose, it will be possible to monitor the rate of release or uptake of the labeled 14C glucose
from the membranes into the aqueous environment. These ‘ghosts’ can also be used to study
the uptake of various molecules at various concentrations under different conditions of
temperatures and the presence of inhibitors for specific molecular uptake.
Problem 3: A 120mg per kg dose of a drug was injected intravenously and its concentration
(mg/L) monitored regularly over time. When log 10 C was plotted vs time (h) a linear response
was obtained with a slope of – 0.08 and an extrapolated y-intercept of 1.3. Calculate the
following pharmacokinetic parameters;
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i. elimination rate constant (k)
ii. initial concentration of the drug in blood plasma (Co)
iii. volume of distribution (Vd)
iv. half-life of drug elimination (t ½).
Solution:
i. Slope = - k/2.303, therefore, k = -2.303x -0.08 = 0.184
ii. Co = Antilog of 1.3 = 10 1.3 = 20 mg/L
iii. Volume of distribution (Vd) = Do/Co = 120/20 = 6 L
iv. The half-life of elimination t1/2 = 0.693/k = 0.693/0.184 = 3.7 hours.
Once the apparent volume of distribution is known for a particular drug the amount of drug
that must be given to achieve a desired concentration can be determined from
Do = Co.Vd
Problem 4: You have been given the following data based on a 65 kg patient; t1/2 of drug X =
4.5hrs, Vd = 0.56L/kg, Cmin the = 5mg/L, C tox = 20mg/L and Css = 10mg/L; calculate:-
i. Drug clearance from the body
ii. Average rate of drug intake (Dosing rate)
iii. Maintenance dose
iv. Maintenance interval
v. Initial loading dose
vi. Loading dose at steady state concentration
Solution
Since t1/2 = 0.693/ k; k= 0.693/ t1/2 i.e. 0.693/4.5=0.154, and V= 0.56 x 65 = 36.4.
i. Total drug clearance = kV = 0.154 x 36.4 = 5.6L/h = 93.3ml/min.
ii. Average rate of drug intake = rate elimination constant
= kxVxCss
= 0.154 x 36.4 x 10
= 56 mg/h
iii. Maintenance dose
= (Ctox - Cther). V
= (20 – 5) x 36.4 = 546 mg
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iv. Maintenance interval = maintenance dose/ rate of elimination
= 546/56
= 9.75 hrs
For a practical loading schedule, the maintenance interval should be lowered to say 8.0 hrs
and the maintenance dose reduced proportionately: = 546 x 8/9.75 ~ 437 mg.
v. The initial loading dose
= Ctox.V
= 36.4 x 20
= 728 mg
vi. The loading dose at steady state
= Css x V
= 36.4 x 10 = 364 mg
Practical problem 1
The analytical method of assaying paracetamol relies on the introduction of a nitro group into
the molecule after the removal of plasma proteins through precipitation. The resultant
nitrophenol compound which is formed has a deep yellow colour in an alkaline medium and
absorbs at 430nm Figure 12.
CH3 C
O
NH
HNO2
OH
NO2
O-
OH-
CH3 C NH
OH
CH3 C NH
NO2
O O
Figure 12. Formation of a chromogenic nitro compound from an analgesic Acetaminophen
i. Describe how you would construct the standard curve for determination of parace‐
tamol concentration.
K=ln X1
X
t1-t2
2. Design an experiment that would enable you to determine the t1/2 of paracetamol
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Practical problem 2
Liver damage can be induced by 20% w/v carbon tetrachloride. Given 10mg/ml pentobarbitone
and 10mg/ml Phenolbarbitone, design an experiment that demonstrates that the duration of
action of short acting barbiturates are dependent on the integrity of the liver.
13. Drug discovery and preclinical trials
The development of new drugs over the past 30 years has revolutionalized the practice of
medicine and has for instance seen the increased use of new anti-hypertensives and drugs that
reduce cholesterol synthesis or dissolve blood clots which led to a 50% reduction in the number
of deaths from cardio-vascular diseases and stroke among other diseases.
13.1. Conventional approaches to drug discovery
These are the classical approaches to drug discovery that do not initially involve detailed
scientific study they include the following;
Traditional knowledge approach
This is the discovery of drugs based on traditional medical knowledge. The best example is
the documented analgesic effects of extracts from opium poppy that led to the isolation of
morphine from the plant and the subsequent synthesis of related analgesics.
Discovery through serendipity
This is the accidental discovery of novel drugs based on the ingenuity of a scientist investi‐
gating a problem initially unrelated to the observed phenomenon; examples of such discov‐
eries include the observation by Alexander Flemmings that penicilliummould could inhibit
the growth of bacteria. This finding led to the discovery of antibiotics.
Discovery of therapeutic usefulness of a side effect e.g. clonidine originally used as a nasal
decongestant was found to have antihypertensive properties while, the hypoglycemic effects
of sulphonamides used in the treatment of typhoid fever led to the development of structurally
related sulphonylureas as oral hypoglycemic drugs.
Discovery from effects of endogenous agents in test animals
An example of discovery arising from studies of endogenous agents in test animals is the
anticoagulant action of the venom from the Malayan viper that led to the identification of the
anticoagulant ancrod.
Modern approaches to drug discovery
These are those approaches that form a basis for the rational design of drugs and include the
following;
Bioprospecting
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This is the screening of a large number of natural products, chemical entities, large libraries of
peptides, nucleic acids and other organic molecules for biological activity. This approach may
lead to identification and development of new drug molecules.
Metabolomics
This is the profiling of natural products of related plant species screening using either liquid
or gas chromatography mass spectrometry to determine active metabolites that may be present
in novel crude herbal medical preparations.
In silico screening
This is the most advanced technique for drug discovery. It entails virtual screening or docking
of compounds on the 3-D- structure of a known receptor based on homologies of the test drug
molecules with a known test parent drug. In silico screening can form a basis for the modifi‐
cation of a known drug molecule to determine possible therapeutic applications and may lead
to the development of putative drugs against new targets.
13.2. Screening of putative drug molecules
Selection of molecules for further study is usually conducted in animal models of human
disease and the pharmacological tests include both the in vitro and in vivo studies after the
initial screening for biological activity. For instance, antibacterial activity of drugs is assessed
by their ability to inhibit growth of a variety of micro-organisms, while hypoglycemic drugs
are tested for their ability to lower blood pressure.
The in vitro  methods include incubation of a parent compound with various subcellular
fractions  such as  microsomes,  individual  recombinant  drug metabolizing  enzymes  from
cells or tissue slices.  The in vivo  studies involve working on typical animal models such
as dogs or rats. Some of the invitro and invivo studies that may be performed are shown
in tables 1 and 2 below;
Target Specific or tissue in vitro studies Biochemical measurement
a. (i) Receptor binding Cell membrane fraction / cloned
receptors
Receptor affinity
(ii) Receptor activity Sympathetic nerves Inhibition of nerve activity
(iii) Enzyme activity Purified enzymes from adrenal
glands
Inhibition of enzyme activity
e.g. tyrosine hydroxylase
b. Cellular function Cultured cells Cell viability
c. Isolated tissue Blood vessels, heart lung or ileum
from rat
Effects on vascular contraction and
relaxation
Table 1. Screening of drugs for specific inhibitory effects on enzymes and isolated tissues.
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Disease model Animal model Route of administration Physiological
measurements
a. Blood pressure Hypertensive rat
(conscious)
Parenteral Systolic/diastolic
b. Cardiac effects Dog (conscious)
Dog (anesthetized)
Oral Electrocardiography
(cardiac output)
Parenteral
c. CNS Mouse, rat Parenteral Degree of sedation
d. Respiratory
effects
Dog/guinea pig Parenteral Respiratory rate and
amplitude
e. GIT effects Rat Oral GIT motility and secretions
Table 2. Putative animal models used in studying effects of drugs
If an agent possesses useful activity it would be further studied for possible adverse effects on
other major organs. These studies might suggest the need for further chemical modification to
achieve desirable pharmacokinetic/pharmacodynamic properties.
13.3. Preclinical trials
The data from animal studies form a basis for the calculation of the initial or starting doses to
be used in the subsequent clinical studies. The human equivalent dose calculations for the
maximum recommended dose are normally based on either the body surface area or body
weight. The candidate drugs that survive initial screening and profiling must be carefully
evaluated for potential risks before and during clinical testing. The main types of evaluation
needed from safety and toxicity studies include:-
Acute toxicity
This involves looking at the effects of large single doses of therapeutic agent. Acute toxicity
studies are usually performed in animal models such as mice and rats. These studies enable
investigators to correlate any observed effects with the systemic level of the drug.
Sub-acute toxicity
This is similar to acute toxicity but measures the effects of multiple doses based on expected
duration of clinical usage. It entails haematological, histology and electron microscope studies
to identify organs which might be affected by toxicity. It usually lasts between one to three
months. This enables the selection of putative compounds for subsequent studies.
Chronic toxicity testing
These studies are required when the drug is intended to be used in humans for prolonged
periods. The goals of this investigation are mostly similar to those of sub-acute toxicity.
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The reproductive performance
These are measurements intended to determine the effects of the drug agents on; mating
behaviour, reproduction, parturition, progeny birth defects, and postnatal development.
Carcinogenicity studies
These studies are required to determine the effects of prolonged usage of the drug under
investigation. They involve hematological and histological autopsy analysis.
Mutagenicity studies
These studies look at the genetic stability and mutations of bacterial or mammalian cells in
culture. These studies are at the academic research level and are intended to provide data for
future research.
Investigative toxicology
The main purpose of toxicology is to discover the pathways that are involved in toxic action.
It includes studies on mechanisms of toxic action of drugs which may lead to the development
of safer drugs.
14. Evaluation of new drugs and drug approval process
Toxicity testing is time consuming and expensive and may require two to five years to collect
and analyze data before the drug can be considered ready for testing in humans.
Large numbers of animals are needed to obtain valid preclinical data.
Extrapolation of toxicity data from animals to humans may not be completely reliable.
The safety or  efficacy of  a  drug must  be thoroughly understood before the drug is  ad‐
ministered  to  any  group  of  individuals.  Therefore  regulations  governing  the  develop‐
ment of new drugs have evolved to assure safety and efficacy of new medications.  The
clinical trials during drug development and post marketing experience form the scientific
basis of patient response to a drug.
Once a drug is judged ready to be studied in humans, a notice of clinical investigational
exemption for a new drug (IND) must be filled with the government body concerned with the
regulation and registration of drugs. The IND includes manufacturing information, all data
from animal studies, clinical plans and protocols and the names and credentials of physicians
who will conduct the clinical trials.
14.1. Phase I clinical trials
The main goal in phase I is to determine whether test animals and humans show signifi‐
cant  different  responses  to  the  drug  and  to  establish  limits  of  the  safe  clinical  dosage
range.  The measurements carried out in phase I  include,  the rate of  absorption,  t1/2  and
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metabolism  of  the  candidate  drug  compound.  The  effects  of  the  drug  as  a  function  of
dosage are established in a small number 25 – 50 of healthy volunteers.  When the drug
is expected to have significant toxicity,  as often the case with cancer and AIDS therapy,
volunteer  patients  with  the  disease  are  used  instead  of  the  healthy  volunteers.  The  re‐
quirements of clinical trials include the following:
i. Homogenous populations of patients must be selected.
ii. Appropriate controls for the investigation must be included.
iii. Meaningful and sensitive indices for drug effects must be used i.e. well defined end-
points such as survival or pain relief should be used rather than surrogate or
intermediate markers e.g. levels of enzymes involved in the process of survival/pain
relief.
iv. The experimental observations must be converted to data and then into valid
conclusions.
v. The accuracy of diagnosis and severity of the disease must be comparable between
the groups being contrasted.
vi. The dosages of the drugs must be chosen and individualized in a manner that allows
relative efficacy to be compared at equivalent toxicities.
vii. Compliance with experimental regimens should be assessed before subjects are
assigned to experimental or control groups. Non-compliance may cause false
estimates of the true potential benefits or toxicity of a particular treatment.
viii. Ethical considerations. These may be the major determinants of the types of controls
that can be used e.g. for therapeutic trials that involve life threatening diseases for
which there is already in-effective therapy, the use of a placebo is considered
unethical. In such cases, new treatments must be compared with standard therapies.
14.2. Study design of phase I trials
For clinical trials to have validity they must be based on a sound statistical basis. Some of the
of the criteria that must be met include;
Randomization
Randomization is a design which ensures that there is no bias in allocation of treatments among
the different groups. The purpose of randomization is to minimize the possibility that an
observed treatment effect is due to inherent differences between groups. Randomization
eliminates bias by avoiding recruiting patients who have a particular characteristic to one
group and not the other e.g. only women/men and smokers/alcoholics. Randomization should
not be carried out until immediately before treatment. The delay allows a patient to have
second thoughts about taking part or the investigator to have to re-consider about admitting
patients to the study. Simple methods of randomization can be designed using published tables
of random numbers, where treatments are in a form of a square in which each treatment is
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contained only once in each row and column and the order of treatment is different in each
group (Table 3).The presence of other diseases or risk factors should be taken into consideration
i.e. need for careful selection and assignment of patients to each of the study groups.
Group Treatment
1 A B C D
2 C D A B
3 D C B A
4 B A D C
Table 3. A random number table array for assignment of various treatment regimes to various groups of patients in
clinical trials
This approach eliminates systematic variation between groups since the patients are allocated
at random order to group 1, 2, 3, or 4. A code list should be drawn up so that the main
investigators may be kept blind to the treatment an individual is receiving but also so that it
is possible to know the treatment by breaking the code. Coding should be such that when
broken, it does not yield information about the treatments other patients are getting. The
treatment information about all the patients should be left to one person preferably the
pharmacist or trial co-ordinator.
Blindness
Blinding is a design which does not allow the investigator to know what treatment the patient
is receiving. The purpose of blinding is to eliminate bias in reporting the outcome of the
treatment since if an investigator knows what treatment the patient is taking, he/she may in
some way influence a measurement or an outcome thus shifting the outcome in one direction
or another consciously or unconsciously. The ideal trial should be double blind where neither
the investigator nor the patient knows what treatment the patient is taking. Placebos or
dummies are used in order to achieve blindness. The placebos should match the active
treatment as closely as possible in terms of size, shape, color, texture, weight, taste and smell
with the active formulation.
Number of testing centers
Clinical trial should be carried out in a defined centre so as to minimize variations in the popula‐
tion and in the investigators techniques. This also avoids problems of data collection, communi‐
cation and follows up. Multi-centre trials may become necessary when studying a rare disease
hence scarcity of patients or when the effect being investigated is small one e.g. when one is
looking out for an interaction effect between a major condition and a minor condition.
Clinical trials designed to evaluate efficacy of new drugs should always be prospective i.e. the
characteristics of the population to be studied should be identified before the study begins.
For example, if one randomized all patients with heart failure to treatment with either digoxin
or a new drug X and then studied the outcome over six months that would be a prospective
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trial. In case of control study the outcome is first identified and then comparisons are made
retrospectively between the characteristics of patients who did or did not have the outcome.
Such a study for instance has shown that oral anticoagulants can reduce incidences of re-
infarction in patients who have already had a myocardial infarction. The case control studies
may be carried out some time, after the introduction of a drug therapy in order to get some
idea of its place in the overall management of the disease since the results of a case control
study may prompt formal prospective trials in order to confirm original findings.
14.3. Molecular markers in drug development
In vitro predictive efficacy and toxico-genomics should be carried out after phase 1 clinical
trials in order to validate the results of the phase 1 clinical trials. This is achieved by using
animal cell lines in which gene expression profiling and patterns of protein production are
used to identity candidate biomarkers for the disease. The utilization of markers that are
associated with the disease or those that indicate a known response to a therapeutic interven‐
tion or reflect a clinical outcome may yield information on efficacy or toxicity of a test drug.
An example of a biological readout that has traditionally been used to determine efficacy
during the treatment of diabetics is the determination of glucose in the urine of a diabetic
patient. Reliable and specific biomarkers that act as predictors of efficacy or long-term toxicity
are useful because they reduce the time, size and cost of clinical trials.
14.4. Phase II clinical trials
These are studies that recruit willing and informed patients and are designed to assess long
term safety, refine pharmacokinetic data, determine optimal dose. The purpose of phase II
studies is to determine efficacy. Typically, phase II trials require 100-150 subjects and take 9-12
months. An assessment of no effect or no worthwhile effect of a given drug demonstrates that
it is futile to proceed with further clinical testing of the drug. It is therefore important to
minimize type I errors or false negatives in the study design in order to minimize the risk of
discontinuing a potentially effective drug. The data from well designed phase I and phase II
trials are therefore critical in planning the subsequent trials. The phase III trials are large trials
intended to determine whether a treatment is effective and to establish safety data.
Phase II clinical trials include inert placebos as negative controls and older active drugs as
positive controls alongside the investigative compound. These studies are done in special
clinical centers such as University Hospitals. A broader range of toxicities may be detected at
this phase.
14.5. Phase III clinical trials
The drug is evaluated in a much larger number of patients (thousands) to further establish
safety and efficacy. Phase III trials are performed in settings similar to those anticipated for
the ultimate use of the drug. After successful phase III trials, the next step is the application
for review of the new drug to seek approval to use the drug for clinical management of the
disease condition.
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14.6. Phase IV clinical trials
This  phase  is  concerned  with  post-marketing  surveillance  and  the  main  goal  is  to  as‐
sess  adverse  reactions,  patterns  of  drug  utilization,  discovery  of  additional  indications.
The  interrelationships  between  the  various  studies  in  drug  development  are  illustrated
in Fig 13 below;
Figure 1.13Illustration of the key steps in the development of a drug from a putative drug 
Crude drug preparation 
Biochemical profiling of 
crude drug product 
In vivo/in vitro 
therapeutic profile for 
test and control model 
In vivo toxicity profiles 
for test and control 
model 
Phase IV 
Clinical trials 
Phase I 
Clinical trials 
Phase II 
Clinical trials 
Phase III 
Clinical trials 
Figure 13. Illustration of the key steps in the development of a drug from a putative drug candidate extract
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14.7. Pharmacogenomics and drug development
The personalized medication which takes into account the genetic make-up of individu‐
als is known as pharmacogenomics. The pharmacogenomic differences that determine in‐
dividualized  therapy  include  genetic  polymorphisms  of  drug  transporters,  drug
receptors, and drug metabolizing enzymes. For example, genetic variation in Cyt P450 en‐
zymes that are largely responsible for drug metabolism shows that different individuals
respond differently  to  drug efficacy or  toxicity.  Genetic  variants  in  the  drug target,  the
disease pathway, genes or drug metabolizing enzymes could all be used as predictors of
drug  efficacy  or  toxicity.  For  example,  drug  monitoring  using  perpherazine,  a  Cyt  P450
substrate, shows that there are three main categories of individuals; the efficient metabo‐
lizers obtained from the heterozygotes, the poor metabolizers from the homozygotes and
the ultra-rapid metabolizers which carry two or more active genes in the same chromo‐
some, a phenomenon known as gene duplication.
The  information  obtained  from  pharmacogenetic  studies  can  be  used  to  design  new
drugs that take the persons’ genetic profile into consideration. The most common type of
genetic variation are single nucleotide polymorphisms, therefore, a high resolution of sin‐
gle  nucleotide  map  may  expedite  the  identification  of  genes  for  various  diseases.  The
molecular profiles of patients identified in phase I and II clinical trials as likely non-res‐
ponders  to  the  putative  drug  under  investigation  might  present  an  opportunity  to  ini‐
tiate new discovery programs for other pharmaceutical compounds.
14.8. Individualized drug therapy
Clinical usage of drugs requires a basic understanding of the pharmacokinetic and pharma‐
codynamic drug processes and an appreciation that a relationship does exist between the
pharmacological effect or toxic response to a drug and the concentration of the drug. The
interpatient and intrapatient variation in disposition of a drug must be taken into account in
choosing a drug regimen.
A drug dosage regimen therefore is a recipe for the administration of a drug so as to pro‐
duce a desired therapeutic effect with minimum toxic effects.
The regimen is described in terms of the following:
i. Dose of the drug to be used and the formulation.
ii. Frequency with which it is administered.
iii. Route of drug administration.
The factors that determine the relationship between the prescribed drug dosage and drug
effect operate at three levels; prescription level, drug administration level and at the physio‐
logical level of patient (Figure 14).
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Prescribed dose 
 Patience compliance 
 Medication errors 
Administered dose 
 Rate and extent of 
absorption 
 Distribution and 
composition of body fluids 
and body size 
Concentration at site of action 
 Physiological variables 
 Pathological and Genetic 
factors 
 Interaction with other 
drugs 
 Development of tolerance 
Intensity of effect 
 Drug - receptor 
interactions 
 Signal transduction 
Figure 14. The operational levels that determine the relationship between prescribed drug dosage and the drug effect.
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Drugs that are excreted primarily unchanged by the kidneys tend to have low variation among
patients with similar renal function than do drugs which are inactivated by metabolism. For
the extensively metabolized drugs, those with high metabolic clearance and large first pass
elimination have marked difference in bioavailability, whereas those with low biotransfor‐
mation tend to have largest variation in elimination rates among individuals.
14.9. Determination of drug dosage
The simplest  way of  determining a drug dosage regimen is  to base it  on the published
recommended dosage.  These are derived from the pharmacokinetics studies of the drug
and the general procedure in using the published recommendations is to start at the low‐
er end of  the recommended dosage range and monitor the therapeutic  effect.  If  the de‐
sired effect  does not occur,  the dosage can be increased gradually until  one reaches the
upper  limit  of  the  range.  In  certain  conditions  it  may  be  necessary  a  sufficiently  high
dose for the drug to accumulate in the body to a satisfactory degree. This dose is known
as the loading dose and is  equal  to  the volume of  distribution multiplied by the target
concentration in  the  plasma.  The reason for  giving a  loading dose  is  to  circumvent  the
sometimes unacceptable time lag preceding the steady state levels. Once the correct load‐
ing dose  is  given,  a  steady-state  concentration can be  achieved rapidly  and then main‐
tained by giving a smaller maintenance dose.
Adjustment  of  dosage  in  individual  patients  is  often  as  a  result  of  the  modification  of
pharmacokinetic parameters of which the three most important include; the bioavailabili‐
ty  or  the fraction of  a  drug that  is  absorbed into systemic circulation,  its  clearance and
the volume of distribution.
For drugs with a high toxicity to therapeutic ratio, the loading dose can be given as a single
dose and for drugs with a low toxicity: therapeutic ratio and a long half-life, the loading dose
can be divided into several portions and given at intervals long enough to allow detection of
adverse effects, but short enough to ensure that the loading dose is a true loading dose i.e.
relatively little amounts of the drug is eliminated from the body during the period of loading.
14.10. Systemic drug availability
The extent of availability of a drug after oral administration is expressed as a percentage of the
dose. The fractional availability (F) varies from 0 to 1. The extent of availability is more
important parameter to measure rather than the rate of availability.
A true decrease in bioavailability could be due to several reasons including, a poorly ad‐
ministered dosage form that fails to disintegrate or dissolve in the GIT, interaction with
other drugs in the GIT, metabolism of the drug in the GIT and/or first pass hepatic me‐
tabolism or biliary excretion.
Hepatic disease may in particular cause high availability because the metabolic capacity
decreases or development of vascular shunts in the liver. Significantly high availability
requires dosage adjustment by a factor of two, while significantly low in availability requires
dosage adjustment by a factor of half.
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14.11. Maintenance dose
In most clinical situations drugs are administered in such a way as to maintain a steady
concentration i.e. just enough drug is given in each dose to replace the drug eliminated since
the preceding dose. Therefore, clearance is the most important pharmacokinetic term to be
considered in defining a rational steady-state drug dosage regimen.
The rate of elimination = Cl x Tc
Where, Cl is the rate of clearance and Tc is the target concentration of the drug.
The Dosing rate = Rate of elimination = Cl x Tc.
Therefore, if the target concentration is known, the prevailing clearance in that patient will
determine the dosing rate and if the drug is given by a route that has a bio availability of less
than 100%, then the dosing rate above can be modified using the formula:
Dosing rate oral =  Dosing rateFractional availability
If intermitted doses are given, then maintenance dose = Dosing rate x Dosing interval.
14.12. Alteration of maintenance dose
The maintenance dose is usually altered when the clearance of the drug changes. For example,
during renal impairment, the clearance of drugs which are predominantly cleared by the
kidney is greatly reduced and therefore, the desired steady state concentration can only be
achieved either through altering the dose or altering the dosing interval. Therefore, when a
drug is cleared almost completely via kidneys, the dosage interval should be changed in
proportion to renal clearance as follows:
The % eliminated in dosing interval should be proportional to creatinine clearance by a
published constant to yield the percentage excreted in one dosage interval.
The quantities required for this adjustment are:
i. Fraction of normal function remaining, and the
ii. Fraction of drug usually excreted unchanged in urine.
The fraction of normal function remaining is equal to the ratio of patient’s creatinine clearance
to a normal value (120 ml/min/70kg).
The following equation is for adjustment of renal clearance
rfpt= 1 – fenl(1 – rfxpt) 
Where;
rfpt = the adjusted total clearance of the patient,
fenl = fraction of drug excreted unchanged in normal individuals,
rfxpt = fraction of renal clearance of the normal individual.
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Clearance should also be adjusted for the size of the patient and for convenience, the published
values are normalized to the metabolic rate = weight 0.75.
When clearance is low, t1/2 is similarly high and when the volume of distribution is high,
the t1/2 is also high. Therefore, by using parameters for the individual patient, the dosing
rate = Tc x Cl/F where, Tc = target concentration, Cl = clearance and F = fractional availa‐
bility of the drug.
If a drug is relatively non toxic then the maximum loading strategy can be employed so that
the dosing interval is much longer than t1/2.. For example t½, of penicillin is less than one hour
but it is usually given in very large doses every six to twelve hours since it is non-toxic. The
normal steady-state theophylline concentration can be determined using the equation:
Css, max = F.dose/Vss1 – exp(-KT)
Css, min = F.dose/Vss.
(exp-KT)
1 – exp(-KT)
Where, Css, max and Css min are the maximum and minimum steady state concentrations,
T = dosage interval and K = 0.693t½
14.13. Drug dosage adjustment in old patients (geriatrics)
Drug absorption in the elderly is slightly different from the normal patients and therefore
adjustment of the dosage should be taken into consideration during drug therapy. The rate of
transdermal drug absorption may be diminished in elderly because of reduced tissue blood
perfusion. Compounds that permeate the intestinal epithelium by carrier mediated transport
mechanisms may be absorbed at lower rates in the elderly.
14.14. Drug distribution
In geriatrics the ‘body mass’ declines with age and the total body water content falls by between
10 – 15%. The volume of distribution of hydrophilic drugs will therefore decrease while plasma
concentration will increase and the likelihood of toxic drug effects will also increase. When
geriatric patients use diuretics, the extracellular space reduces even further leading to a higher
likelihood of drug toxicity. The total body fat in the elderly increases by 12 – 18%, therefore,
for hydrophobic drugs, the higher volume of distribution implies an increase in half life of
distribution and the time needed to reach steady-state serum concentration. Therefore, for
geriatrics a once or twice daily drug administration is optimal. This can be achieved though
delayed release or fixed drug combinations.
14.15. Patient compliance and rational use of drugs
Drug treatment of any kind is often compromised by lack of full compliance by the patient.
The common errors of compliance to a regimen by a patient include; omission in taking the
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drug, wrong timing of dosages, premature termination of therapy or using additional
medications. In order to improve patient compliance, the patient should be made to under‐
stand the nature and prognosis of the illness and what to expect from the medication by
detailing both the acceptable and undesirable unwanted effects as well as signs of efficacy that
may help enforce compliances.
Patients frequently discontinue taking a medication such as septrin because they have not been
told the necessity of continuing with the drug after the acute symptoms have subsided.
The effectiveness of physician-patient communication is inversely related to the error rate in
the taking of drugs. A physician might prescribe a drug to be taken three times a day with
meals for a patient who either eats only twice a day or sleeps all day and works at night.
Therefore, an exploration of the patients eating, sleeping and working habits is necessary
before a prescription is given.
The educational level of a patient may also require that the prescription is carefully worded
and oral instructions given in the primary language of the patient since when such patients
take three or more medications they are less likely to use them properly. It is therefore
important to provide identifying symbols for each medication e.g. “Heart pill” or “sugar
pill”and to reduce the doses into once or twice daily regimens.
14.16. Adverse drug reactions
Pharmacological formulations are potentially harmful to the individuals taking the drugs.
There is need to ascertain the safety of new drugs before allowing them to be marketed.
The  following figures  highlight  the  magnitude  of  the  problem:  ~  10  –  20% of  hospital‐
ized patients suffer adverse drug reactions, while 0.3 – 5.0% inpatients admissions and ~
0.3% deaths in hospital are due to adverse drug reactions. Adverse drug reactions can be
classified into two main categories:  They may be dose related or non dose related with
each being short-term or long-term.
14.17. Dose related adverse reactions
Adverse drug reactions can occur because of the changes in the systemic availability of a
formulation. For instance, the change of excipients in phenytoin capsules from CaSO4  to
lactose  leads to  high availability  and hence adverse  drug reactions.  Sometimes,  adverse
drug reactions can occur due to the presence of contaminants like bacteria if quality con‐
trol  breaks  down.  Out-of-date  formulations  may  also  cause  adverse  drug  reactions  be‐
cause of degradation products arising from the drug e.g. outdated tetracycline may cause
Faconis  Syndrome (a  type  of  rickets)  because  of  the  transformation  product,epiandrote‐
tracycline. Dose related adverse reactions may also arise from pharmacokinetic variations
in the individuals taking the drug. Pharmacokinetic variations may also arise due to hep‐
atic disease like advanced cirrhosis which lowers the clearance of drugs such as pheny‐
toin and morphine. The pharmacological variations could be environmental such as diet
or smoking, while others are genetic.
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14.18. Non-dose related adverse drug reactions
These include immunologic reactions and are related to the surface proteins present on β-
humans lymphocytes (HLA antigens) which are important in the function of T-lymphocytes.
The association of HLA antigens with foreign antigens stimulates T-lymphocytes. Some of
these antigens expressed by major histocompatibility complex (MHC) genes have been
associated with an increased risk of adverse drugs e.g. nephrotoxicity from penicillamine is
increased in patients with HLA types B8 and DR 3 while patients with HLA- DR, 7 are protected
against adverse drug effects.
14.19. Types of drug allergies
Drug allergies can be classified into five categories:
Type I
This anaphylaxis or immediate hypersensitivity reactions; the body reacts within five to thirty
minutes. The IgE molecules fixed to mast cells and basophil leucocytes release histamine and
other pharmacological mediators such as kinins. Drugs likely to cause are anaphylactic shock
include;-penicillins, streptomycin, local anaesthetics etc.
Type II
In these reactions, the circulating antibody of 1gG, 1gM or 1gA interacts with the drug
combined with a cell membrane protein to form a hapten-protein/antigen-Ab complex. This
leads to the activation of the complement leading to cell lysis of phagocytic attack of the cell
with the complex. Drugs such as the cephalosporins, penicillins, quinine and transfusion of
improperly matched blood can yield this type of reactions.
Type III
In this type of allergy, the immune complex reactions initiate an inflammatory response due
to the combination of the excess drug- protein complex with the IgG in circulation. The complex
thus formed is deposited in the tissues and causes activation of the complement and damage
of capillary endothelium. This type of reaction is manifested mostly as fever, arthritis, and/or
enlarged lymph nodes. Penicillins, sulphonamides and streptomycin may elicit type III allergic
reactions.
Type IV
This is the cell-mediated or delayed hypersensitivity reactions in which the T - lymphocytes
are sensitized by a hapten to form protein-antigenic complex such that when the lymphocytes
come into contact with the antigen, an inflammatory response ensues. Type IV reactions are
exemplified by contact dermatitis caused by local anaesthetic areas, antihistamine areas,
topical antibiotics and antifungal drugs.
Type V
These are pseudo allergic reactions, that resemble allergic reactions clinically, but for which
no immunological basis can be found, e.g. asthma and skin rashes caused by aspirin. Admin‐
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istration of ampicillin or amoxicillin causes a skin rash which resembles the one caused by
penicillin hypersensitivity. The ampicillin-caused rash can be distinguished from penicillin
hypersensitivity on the basis of two features; it has a later onset, typically ten to fourteen days,
compared to penicillin sensitivity which comes between seven to ten days. Furthermore, the
sensitivity does not recur following re-exposure to ampicillin and is not as serious as the one
caused by penicillin.
14.20. Clinical evaluation of adverse drug reactions
The two basic approaches for clinical evaluation of adverse drug reactions include the cohort
studies (or follow-up studies) of patients taking the drug and the case control studies which
record the incidences of adverse drug effects retrospectively.
Cohort or prospective studies
In cohort studies, drugs are identified and incidences of adverse effects recorded. The weak‐
nesses of these studies include; the relatively small number of patients likely to be recruited,
and lack of suitable control groups to assess the background incidence of any apparent adverse
reaction noted.
Case control or retrospective studies
The approach here is to start with the incidence of adverse reaction(s) and then look for the
drug and the individuals with symptoms which could be due to an adverse drug reaction.
These individuals are screened to see if they had taken the drug. The prevalence of drug taking
in the group is then compared with the prevalence in a reference population which did not
take the drug. This approach is excellent for validation and assessment of adverse drug effects,
but it may not detect new adverse effects. Furthermore, it requires a very large number of
patients and is very expensive to undertake hence difficult to justify and organize for every
new product.
14.21. Worked examples
Problem 5
Drug clearance must always be adjusted for alterations of renal function using the formula:
rfpt = 1 - fenl (1 - rfxpt),where fenl = fraction of the drug excreted unchanged in normal individuals,
rfpt = adjustment factor for total clearance in patient, rfxpt = patients’ clearance as a fraction of
normal clearance and Clnl= normal clearance.
Given that an asthmatic patient has a creatinine clearance of 40mlmin-1 70kg-1 and that the
fraction of terbutaline excreted unchanged, fenl= 0.56, the normal clearance,Clnl = 3.4
ml/min/kg, calculate the clearance of the drug in the patient.
Solution
The patient has depressed renal function: rfxpt = (40 ml/min)/ (120 ml/min) = 0.33
rfpt= 1 - fenl(1-rfxpt)
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inline formula rfpt= 1 - 0.56 (1 - 0.33) = 0.62
inline formula 
Clpt= Clnl.rfpt
 = 3.4ml.min-1kg-1x 0.62
 = 2.1ml.min-1kg-1
Problem 6
Given the following characteristics of drug A; t½ = 8h, given at a dosage of 450mg every 12h,
has Vss = 0.5 L/kg, effective concentration is 12mg/L and that
Cssmin =  
F  x dose / V ss(ex p −kt)  
1 –  ex p (−KT )
Css, max =
F x dose/Vss
1 – exp(-kT)
Determine the Cssmin and Cssmax for a 60 kg patientif F = 1 and expKT = 0.35. Explain how
changing of the dosage interval to 6 hours would affect Cssmin.
Solution
The term exp(-KT) is the fraction of the last dose that remains in the body at the end of a dosing
interval and is equal to 0.35 and Css min = Css max.exp(-kt). Therefore,
Cssmin = 450/30 x 0.351- 0.35 =15/0.65 x 0.35 ~ 8.0 mg/L while Cssmax =15/0.65=23 mg/L
The predicted minimum of 8.0mg/L is below the effective concentration to achieve efficacy.
Therefore the dosing interval should be reduced. A reduction of the interval to, say, six hours,
increases denominator and therefore causes an increase of Cssmin. Since t1/2 = 0.693/K, K = 0.086
i.e. 1 - e-KT = 1 - 2.71-0.086 x 6 = 1 - 0.596 = 0.4.
The new Css minimum becomes; = 450/30 x 0.4 = 15 mg/L which is within the required thera‐
peutic concentration.
Review exercise
1. Write an essay on statistical considerations that guide clinical evaluation of new drug
agents
2. Write an essay on bioprospecting for new antimicrobial agents.
3. Drug clearance must always be adjusted for alterations of renal function using the
formula: rfpt = 1- fenl (1- rfxpt), explain what each term in the above equation represents.
Consequently, calculate the clearance of acetaminophen (panadol) in a 70 kg patient with
depressed renal function given the following; normal clearance = 350 ml min -170 kg; fenl
= 0.56. The patient creatinine clearance = 80 mlmin-1 70 kg. Normal creatinine clearance =
120 ml min-1 70 kg. What effect would the impaired renal function have on dosing interval?
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4. Given that fenl for drug X = 0.42, and the normal creatinine clearance is 120 ml/min/70 kg,
calculate the clearance rate of the drug by a patient with creatinine clearance of 75 ml/min/
70 kg.
5. Write an essay on adverse drug reactions associated with the use of macrolide antimicro‐
bial agents.
Author details
Gabriel Magoma
Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology. Nai‐
robi, Kenya
References
[1] Christoph & F., Heike Brotz-Oesterhelt (2005). Functional genomics in antibacterial
drug discovery. Today Targets DD. 10
[2] David, A. L. and Michael P. W. (2004). Molecular biomarkers in drug development.
Research Focus DDT. 9, 22
[3] Di Bernardo, A.B. and Cudkowicz, M.E. (2006). Translating preclinical insights into
effective human trials in ALS. Biochemicaet Biophysica Acta1762, 1139 -1149.
[4] Harvey A, L. (2007). Natural products as screening source. Current Opinions in Chemical
Biology.11, 480 - 484.
[5] Jaennefer M. F., Paul, A. L. (2000) Emerging novel antifungal agents. Therapeutic focus.
DD. 5, 1 January 2000
[6] Iris, R. (2008). PK/PD Modelling and simulations: utility in drug development. Drug
Discovery Today.348, 1 - 6.
[7] Klaus, T. (2003).When drug therapy gets old: pharmacokinetics and pharmacodynam‐
ics in the elderly. Experimental Gerontology38 843-853.
[8] Kieran, F. R., Eric S. and Philip H. W. (2001).Modelling and simulation in clinical drug
development. Research Focus DD Vol. 6, 15
[9] Lindpaintner, K. (2002). The Impact of pharmacogenetics and pharmagenomics on
drug discovery. Naure Review on Drug Discovery.1, 463 - 469.
[10] Sundbergh, M. I. (2001). Genetic susceptibility to adverse effects of drugs and environ‐
mental toxicants. The role of the CYP family of enzymes Mutants Researh 482. 11-19
Drug Discovery514
[11] Timothy, D. R., Steven R.G., Herve, T., Brian A.D. (2001). Finding drug targets in
microbial genomes. Drug Discovery Today6, (17): 887-892.
[12] Tim, R. C. and Marc L. (2007). Pharmacogenitics of antiretroviral drugs for the treat‐
ment of HIV-infected patients: An update. Infection, Genetics and Evolution 7, 333-342
[13] Turnheim, K. (2003). Why drug therapy gets old Pharmacokinetics and pharmacody‐
namics in the eldery. Experimental Gerontology 38 843-853.
[14] Paul, B. (2003). Toxicokinetics in preclinical evaluation. Research Focus DD Vol. 8
[15] Ulrich, R., Friend, S. H. (2000). Toxicogenomics and drug discovery: Will new technol‐
ogies help us produce better drugs? Nat. Rev. Drug Discov. 1, 84 – 88.
[16] Werbovetz, K. A. (2000). Target based drug discovery for Malaria, Leishmania and
Trypanosomiasis. Current medicinal Chemistry 7 (8) 835 – 860.
[17] Aungst B. (2000). Intestinal permeation enhancers. Journal of Pharmacological Sciences,89
(4), 429-442.
[18] Salama, N.N. Eddington N.D. Fasano, A. (2006).Tight junction modulation and its
relationship with drug delivery. Advanced Drug Delivery Reviews.58: 15-28.
[19] Guengerich F. P. (2001). Common and uncommon cytochrome P450 reactions related to
metabolism and chemical toxicity. Chemical Research and Toxicology.14: 611 - 650.
[20] Blanka R., (1998). Receptor-mediated targeted drug or toxin delivery. Advanced Drug
Delivery Reviews 29: 273-289.
[21] John R. C. (2005). Some distinctions between flavin-containing and cytochrome
P450monooxygenases.Biochemical and Biophysical Research Communications 338: 599-604.
[22] Xiaoling L. William K. C. (1999). Transport, metabolism and elimination mechanisms
of anti-HIV agents. Advanced Drug Delivery Reviews29: 273-289 39, 81-103.
[23] Brown, M.J., Bennet, P.N., Lawrence, D.R. (1997). Clinical pharmacology (8th Edition)
Wesley, Longman China Ltd.
[24] Hardman J.G., Gilman A.G., Limbird L. E.(1996). The pharmacological basis of therapeu‐
tics (9thEdition) McGraw-Hill.
[25] Katzung B. G.,(2004). Basic and clinical pharmacology (9th Edition) Mcgraw Hill Inc.
Introduction to Biochemical Pharmacology and Drug Discovery
http://dx.doi.org/10.5772/52014
515

